Fimbrion Therapeutics, Inc., under its joint research collaboration with GlaxoSmithKline, has identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). The Discovery Partnership began its joint research efforts in July 2016.    The newly identified clinical candidate is a mannose-containing small molecule that targets an adhesive protein in bacteria called FimH. This drug candidate represents a new strategy for tre...